Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Accumulated Depreciation & Amortization (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $141.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 17.51% to $141.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141.7 million through Dec 2025, down 17.51% year-over-year, with the annual reading at $141.7 million for FY2025, 17.51% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $141.7 million at BeOne Medicines, up from $105.7 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $171.8 million in Q4 2024, with the low at $9.6 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $60.3 million, with a median of $47.4 million recorded in 2021.
  • The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 95.91% in 2024, then decreased 17.51% in 2025.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $46.5 million in 2021, then skyrocketed by 42.67% to $66.3 million in 2022, then skyrocketed by 32.28% to $87.7 million in 2023, then surged by 95.91% to $171.8 million in 2024, then fell by 17.51% to $141.7 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $141.7 million, $105.7 million, and $68.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.